http://www.biofocus.com/news.htmThe latest headlines and articles from BiofocusGalapagos’ service companies, BioFocus and Argenta, today announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases.http://www.biofocus.com/news,biofocus-and-argenta-announce-drug-discovery-collaboration-with-astrazeneca-in-respiratory-and-inflammatory-disease_235.htmWed, 14 Mar 2012 08:46:00 GMTAlmirall, S.A. announced today that it has formed a research alliance with BioFocus, an affiliate from Galapagos NV (Euronext: GLPG). The three-year alliance is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall. Under the terms of the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort. The value of this collaboration to BioFocus could reach €7.5 million.http://www.biofocus.com/news,almirall-and-biofocus-enter-research-alliance_227.htmWed, 25 Jan 2012 08:48:00 GMTBioFocus, an integrated drug discovery partner, today announced that it has enhanced its diverse screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge. BioFocus now offers one of the most powerful screening platforms in the industry with over 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.http://www.biofocus.com/news,biofocus-creates-novel-diverse-screening-library_215.htmMon, 05 Dec 2011 08:42:00 GMTBarcelona, Spain, and Saffron Walden, UK, November 15, 2011. The pharmaceutical company Almirall S.A. and BioFocus, an integrated drug discovery partner, today announced they have entered into a collaboration agreement to find new hit compounds against key targets of interest to Almirall.http://www.biofocus.com/news,almirall-and-biofocus-announce-collaboration-to-find-new-hit-compounds-against-key-targets_213.htmTue, 15 Nov 2011 10:02:00 GMTBioFocus announced today that it has extended its collaboration with Chiesi Farmaceutici, a privately owned Italian pharmaceutical company, for a second time. This extension of the collaboration with Chiesi is valued at €2.8 million.http://www.biofocus.com/news,biofocus-announces-second-extension-to-collaboration-with-chiesi_209.htmWed, 12 Oct 2011 06:34:00 GMTGalapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).http://www.biofocus.com/news,argenta-and-biofocus-announce-twoyear-extension-of-drug-discovery-collaboration-with-genentech_207.htmThu, 18 Aug 2011 06:30:00 GMTBioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.http://www.biofocus.com/news,biofocus-and-intermed-discovery-announce-marketing-collaboration_205.htmTue, 19 Jul 2011 08:12:00 GMTBioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.http://www.biofocus.com/news,biofocus-enters-collaboration-with-michael-j-fox-foundation_204.htmWed, 13 Jul 2011 08:25:00 GMTBioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.http://www.biofocus.com/news,biofocus-extends-collaboration-with-usher-iii-initiative_202.htmTue, 21 Jun 2011 09:29:00 GMTEvotec AG (Frankfurt Stock Exchange: EVT; TecDAX) and Galapagos NV (Euronext: GLPG) today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. http://www.biofocus.com/news,evotec-acquires-compound-management-business-from-galapagos_200.htmWed, 01 Jun 2011 09:07:00 GMTBioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration. http://www.biofocus.com/news,astellas-pharma-and-biofocus-sign-target-discovery-agreement_196.htmThu, 12 May 2011 08:46:00 GMTBioFocus announced today it has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full rights to discover, develop and commercialize novel medicines on these targets. http://www.biofocus.com/news,biofocus-delivers-validated-oncology-targets-to-janssen_194.htmWed, 20 Apr 2011 08:54:00 GMTBioFocus announced today that it has entered into collaboration with Almac allowing BioFocus customers with compound screening and profiling requirements to access Almac’s FLEXYTE™ fluorescence lifetime (FLT) assays. Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling. http://www.biofocus.com/news,biofocus-and-almac-collaborate-to-offer-fluorescent-lifetime-assays_167.htmMon, 28 Mar 2011 08:43:00 GMTBioFocus announced today that its Compound Focus, Inc. subsidiary has signed a compound management services agreement with the University of Nottingham, UK. Under the terms of this agreement, Compound Focus will select, source, acquire, perform quality control checks, and reformat a compound collection before returning to the Managed Chemical Compound Collection (MCCC) at the University of Nottingham. These services will be provided by Compound Focus’ compound management facility in South San Francisco, USA. http://www.biofocus.com/news,university-of-nottingham-and-biofocus-sign-compound-management-agreement_166.htmMon, 21 Mar 2011 13:24:00 GMTBioFocus announced today that it has established an innovative and unique model for the sale of its SoftFocus compound libraries. Going forward, BioFocus will provide a limited number of clients with SoftFocus libraries on a subscription basis only. These libraries are designed to target protein families of particular interest to the subscribers. This shared exclusivity model will allow clients access to high value, novel compounds with limited competition on derived intellectual property. http://www.biofocus.com/news,biofocus-leads-compound-library-market-with-innovative-business-model_165.htmTue, 15 Mar 2011 13:00:00 GMTBioFocus announced today that its Compound Focus, Inc. subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck’s liquid chemical library collection, distributing screening sets to high throughput screening centers in both USA and Europe. These services will be provided by Compound Focus’ compound management facility in South San Francisco, USA.http://www.biofocus.com/news,lundbeck-research-usa-inc-and-biofocus-sign-compound-management-agreement_161.htmWed, 26 Jan 2011 08:18:00 GMTOno Pharmaceutical Co., Ltd. (Osaka, Japan) and BioFocus (Saffron Walden, UK) announced today that they have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune disease. Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration. BioFocus will utilize its unique SilenceSelect® target discovery platform to deliver validated targets for Ono’s immunology programs. Ono aims to find modulators for these targets and generate novel and innovative drug candidates.http://www.biofocus.com/news,ono-and-galapagos-subsidiary-biofocus-sign-target-discovery-agreement-in-the-field-of-autoimmune-disease_157.htmTue, 11 Jan 2011 08:02:00 GMTBioFocus announced today that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services. Under the terms of the extended agreement, BioFocus will receive €2.0 M ($2.6 M) in research fees for the first year. Additionally, BioFocus is eligible to receive payments of access fees and success-based milestones.http://www.biofocus.com/news,biofocus-extends-collaboration-with-amgen-into-2012_156.htmFri, 17 Dec 2010 08:38:00 GMTBioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, announced today that is has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5 million.http://www.biofocus.com/news,biofocus-extends-collaboration-with-chiesi_151.htmThu, 14 Oct 2010 09:09:00 GMTBioFocus announced today that its Compound Focus subsidiary has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (€3.7 M), with two one-year extension options.http://www.biofocus.com/news,biofocus-and-the-national-cancer-institute-sign-compound-management-agreement_150.htmTue, 12 Oct 2010 09:18:00 GMT(c) 2012, Biofocus. All rights reserved.5